the next path
to cell and
gene therapy
success...
Cell and gene therapies are revolutionizing patient treatment and leading to cures for cancer and genetic diseases. However, to unlock the full potential of these advanced therapies, we need to overcome complex and unique challenges in development and manufacturing.

The drug discovery and development pathway for cell and gene therapies deviates from traditional approaches. Due to the complexities surrounding scaling up of manufacturing, it’s important to have systems and instruments in place that are proven to seamlessly work together.

Whether you are working on early-stage research or need to efficiently scale up processes to fully GMP-compliant manufacturing, partnering with the right supplier of products and services can accelerate your path to success and bring your therapy to patients faster.

We successfully produced more than 2000 GMP batches
Our offer

At Lonza Pharma & Biotech, we are passionate about helping you accelerate the development of cell and gene therapies to get new treatments to patients faster.

Our scientists and engineers are dedicated to developing new technology platforms that are specifically designed to increase pipeline efficiencies. Our portfolio of research and manufacturing media, non-viral transfection technologies, primary cells and testing products support you through every step of the development and production of your cell and gene therapy.

Together with our Cell and Gene Therapy Development and Manufacturing Services, we can help you successfully navigate the path from early discovery to commercialization, and make your journey as easy as possible.

Why Lonza

Scalable technologies
Your needs are different depending upon where you are on the clinical development path. Our products deliver reproducible results and cost-efficiencies, and are available at research and manufacturing grades, in various volumes and formats.

Accelerate success
Time to market is a critical success factor for cell and gene therapies. Working with one trusted and experienced partner from discovery to commercialization prevents unnecessary iteration cycles.

De-risked process development
Systems that do not effectively work together pose a major risk for cell and gene therapy pathways and can result in lengthy delays and additional costs. We designed our platforms to work seamlessly together, helping to de-risk and accelerate your process development.

Products and expert support from one source
Our Cell and Gene Therapy product portfolio, and Development and Manufacturing Services, combined with an experienced Scientific Support team and proficient engineers, can help find you fastest path and overcome any challenges along the way.

Technology platforms tailored to your needs

TheraPEAK™ Media
Our therapeutic cell culture media accelerate speed to market with robust, consistent and cost-efficient processes for cell and gene therapies. We continuously develop new products building on our expertise in regulatory and process efficiency, to meet the requirements of future manufacturing processes. Using TheraPEAK™ Media Products with Lonza systems and services provides you with an end-to-end solution that can be easily adapted to various cell and gene therapy platforms.

Nucleofector™ Technology
Our platform for non-viral, ex vivo transfection of human primary cells can transform workflows. The flexible electroporation-based platform supports numerous applications, such as CAR-T cell generation, CRISPR genome editing, or iPSC reprogramming. Ranging from small-scale to large-scale formats, Nucleofector™ Products allow you to quickly translate research results into cell therapeutic applications. Using our TheraPEAK™ Nucleofector™ Consumables will further expedite your path towards a GMP process.

Primary cells and tissues
Our highly characterized, research-grade hematopoietic stem cells (CD34+ cells) are immediately available from bone marrow, mobilized blood, and cord blood. Additionally, using our diverse, established network we can find your specific donor and perform the time-consuming cell isolations and qualification through a robust QC process. Beyond CD34+ cells, we can offer an extensive portfolio of immune cells, such as PBMCs, T Cells, and NK cells to support your cell and gene therapy projects. Whether it’s readily available cryopreserved cells or made-to-order from fresh whole tissue, we can help reach your discovery destination, faster.
Cell and Gene Therapy Development and Manufacturing Services
With decades of scientific and engineering experience, our team provides you with an extensive service offering that includes tailored process and analytical development, cGMP manufacturing, and regulatory services. We are constantly investing in technologies and expertise to effectively support the development and commercialization of your therapy. Therefore, we created four Centers of Excellence for Cell and Gene Therapy globally across three continents to help customers get new therapeutics to patients faster.

Endotoxin Detection
The Bacterial Endotoxin Test (BET) is a crucial regulatory requirement to ensure safety of any therapeutic before parenteral administration, and is specifically required before cells are transfused back into a patient. Endotoxin from gram-negative bacteria is the most potent pyrogen that may cause fever, septic shock or even death. With patient safety in mind and decades of experience, we provide a wide range of regulatory compliant testing solutions and services to ensure that your cell therapeutic can be used with confidence.

MODA™ Solution
The MODA™ Platform is a configurable, flexible and powerful solution for paperless data capture in laboratories and manufacturing facilities. With GMP compliance and tracking at its core, the MODA™ Platform provides a cost-effective solution that is easy to implement and maintain. To best meet your needs, we developed the MODA-ES™ Platform, which enables real-time data capture and eliminates calculation errors for improved workflow decisions.

Cocoon® Platform
Our Cocoon® Platform for automated and functionally closed patient-scale cell therapy manufacturing offers end-to-end manufacturing with integrated unit operations. Workflow steps automated include selection, activation, transduction/transfection, expansion, and harvest/final formulation. Flexible single-use components and programming enable an efficient path from early process development to commercial GMP manufacturing.
Your path from discovery to commercialization — we’ll walk it together

With a comprehensive portfolio of products and services, we can seamlessly support cell and gene therapy workflows from discovery to commercialization. Together with our technical support team we can help to minimize time to market — and thereby shorten your path to success.

<table>
<thead>
<tr>
<th>Discovery</th>
<th>Translational</th>
<th>Clinical trials</th>
<th>Commercial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary cells and tissues</td>
<td></td>
<td>Primary cells and tissues</td>
<td></td>
</tr>
<tr>
<td>Research media</td>
<td></td>
<td>TheraPEAK™ Media for manufacturing</td>
<td></td>
</tr>
<tr>
<td>Nucleofector™ Products for research</td>
<td></td>
<td>TheraPEAK™ Nucleofector™ Products for manufacturing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pyrogen and endotoxin testing</td>
<td>MODA™ Platform – EBR and QC Data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CoCoon™ Platform, automated, patient-scale manufacturing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cell and gene therapy development and manufacturing services</td>
</tr>
</tbody>
</table>

Our products and services in cell and gene therapy processes

1. Isolation
2. Pre-stimulation expansion
3. Genetic modification
4. Expansion
5. Characterization testing

- 2, 4: TheraPEAK™ Media and Reagents
- 3: TheraPEAK™ Nucleofector™ Products
- 2 – 4: The Cocoon® Platform
- 4, 5: Endotoxin Testing
- 4, 5: MODA™ Solutions
- 1 – 5: Cell and Gene therapy Development and Manufacturing Services
- PD, T: Primary cells and tissues for Process Development (PD) and Training (T)
Contact us

North America
Customer Service:  +1 800 638 81 7 4 (toll free)
Fax: +1 301 845 8338
order.us@lonza.com
Scientific Support:  +1 800 521 0390 (toll free)
scientific.support@lonza.com

Europe
Customer Service:  +32 87 32 1 6 11
order.europe@lonza.com
Scientific Support: +32 87 321 611
scientific.support.eu@lonza.com

International
Contact your local Lonza distributor
Customer Service:  +1 301 898 7025
scientific.support@lonza.com
www.lonza.com/products-for-cell-and-gene-therapy

Nucleofector™ Technology and Primary Cell Systems are for research use only and are not intended for human therapeutic or diagnostic use. All Therapeutic Products are produced according to applicable GMP standards and follow the USP/EP guidance for cell and gene therapy raw materials. It is the end user’s responsibility to ensure full compliance with local regulations in terms of safety assessments and effective removal prior to patient exposure.

All trademarks belong to Lonza or its affiliates or to their respective third party owners.

The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risk of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party’s intellectual property rights. For more details: www.lonza.com/legal

©2021 Lonza. All rights reserved. [1 800 638 8174] 2/21